NCT02843074 - Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

July 27, 2021

Study Completion Date

October 5, 2021

Conditions

Multiple Myeloma

Interventions

DRUG

elotuzumab

Given intravenously (IV)

DRUG

Lenalidomide

Given by IV

DRUG

Dexamethasone

Given orally (PO) or by IV

PROCEDURE

autologous stem cell transplantation

Trial Locations (6)

Center for Cancer and Blood Disorders, Bethesda

Tennessee Oncology, Nashville

Tennessee Oncology, Chattanooga

HCA Midwest Health/Research Medical Center, Kansas City

Nebraska Methodist Hospital, Omaha

Colorado Blood Cancer Institute, Denver